1
Home
Companies

Edgewise Therapeutics

Edgewise Therapeutics
Leadership team

Dr. Kevin Koch Ph.D. (Pres, CEO & Director)

Dr. Badreddin Edris Ph.D. (Co-Founder & Independent Director)

Dr. Behrad Derakhshan Ph.D. (Chief Bus. Officer)

Products/ Services
Biopharma, Biotechnology, Health Care
Number of Employees
0 - 50
Headquarters
Boulder, Colorado, United States
Established
2017
Company Registration
SEC CIK number: 0001710072
Traded as
NASDAQ:EWTX
Social Media
URL
https://www.edgewisetx.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
History

Edgewise Therapeutics is a biopharmaceutical company that was founded in 2014 by a team of scientists from the University of California, San Francisco. The company focuses on developing drugs that can address unmet medical needs in serious and life-threatening diseases. Edgewise Therapeutics is headquartered in San Francisco, California and has a research laboratory in South San Francisco, California.

Mission
Our mission is to develop innovative drug therapies that can help patients suffering from serious and life-threatening diseases.
Vision
Our vision is to become a leader in the development of innovative drugs for treating serious and life-threatening diseases.
Key Team

Dr. Joanne M. Donovan M.D., Ph.D. (Chief Medical Officer)

Dr. Alan J. Russell Ph.D. (Co-Founder, Chief Scientific Officer & Director)

Mr. R. Michael Carruthers (Chief Financial Officer)

Mr. John R. Moore (Gen. Counsel)

Dr. Marc Semigran M.D. (Chief Devel. Officer)

Recognition and Awards
Edgewise Therapeutics has been recognized for its innovative research and development efforts. The company has received numerous awards, including the Biotech of the Year Award from The Scientist Magazine and the Drug Discovery Award from the International Society for Pharmaceutical Engineering.
References

https://in.investing.com/equities/edgewise-therapeutics

https://finance.yahoo.com/quote/EWTX/profile?p=EWTX

https://www.crunchbase.com/organization/edgewise-therapeutics

https://www.edgewisetx.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Edgewise Therapeutics
Leadership team

Dr. Kevin Koch Ph.D. (Pres, CEO & Director)

Dr. Badreddin Edris Ph.D. (Co-Founder & Independent Director)

Dr. Behrad Derakhshan Ph.D. (Chief Bus. Officer)

Products/ Services
Biopharma, Biotechnology, Health Care
Number of Employees
0 - 50
Headquarters
Boulder, Colorado, United States
Established
2017
Company Registration
SEC CIK number: 0001710072
Traded as
NASDAQ:EWTX
Social Media
URL
https://www.edgewisetx.com